Lipoprotein (a) is associated with basal insulin levels in patients with type 2 diabetes mellitus;Lipoproteína (a) está associada com níveis basais de insulina em pacientes com diabetes mellitus tipo 2

Arquivos Brasileiros de Cardiologia

Volumn 93, Issue 1, 2009, Pages 28-33

  Habib, Syed Shahid ^a   Aslam, Muhammad ^a   Shah, Syed Fayaz Ahmad ^a   Naveed, Abdul Khaliq ^a  

^a NONE

Author keywords

Diabetes mellitus; Dyslipidemias; Insulin; Lipoprotein (a)

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; FEMALE; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; INSULIN; LIPOPROTEIN(A); MALE; TRIGLYCERIDES;

EID: 70449364815     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2009000700006     Document Type: Article

References (35)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595-1607
2. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14: 173-194
3. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991; 34: 416-422
4. Fanci D, Braunwald I, Isselbacher S, Wilson W, Martin A, Kasper C, et al. Diabetes Mellitus. In: Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998. p. 2060-2086
5. Saad MF, Knowler WC, Pettitt J, Nelson RG, Charles MA, Bennett PH. A two step model for development of non-insulin- dependent diabetes. Am J Med. 1991; 90 (2): 229-235
6. Leahy JL. Natural history of beta cell dysfunction in NIDDM. Diabetes Care. 1990; 13 (9): 992 1010.
7. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes. 2006; 55 (4): 1114-1120 (Pubitemid 44100189)
8. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol.1993; 137: 959-965
9. Tennyson GE. Understanding type 2 diabetes mellitus and associated cardiovascular disease: linked by insulin resistance. Am J Manag Care. 2002; 8 (16 Suppl): S450-9.
10. Balkau B, Eschwege E. Insulin resistance: an independent risk factor for cardiovascular disease? Diabetes Obes Metab.1999; 1 (Suppl 1): S23-31.
11. Kostner KM, Kostner GM. Lipoprotein(a): still an enigma? Curr Opin Lipidol. 2002; 13: 391-396
12. Ribault A, Durou MR, Letellier C, Wojcik F, Poirier JY, Ruelland A. Determination of lipoprotein(a) concentrations and apolipoprotein(a) molecular weights in diabetic patients. Diabetes Metab. 2000; 26 (2): 107-112 (Pubitemid 30307581)
13. Habib SS, Aslam M. High risk levels of lipoprotein(a) in Pakistani patients with type 2 diabetes mellitus. Saudi Med J. 2003; 24 (6): 647-651
14. Woo J, Lam CWK, Kay R, Woing HY, Teoh R, Nicholls MG. Acute and long term changes in serum lipids after acute stroke. Stroke. 1990; 21: 1407-1411 (Pubitemid 20339707)
15. Bartens W, Rader DJ, Talley G, Brewer HB Jr. Lipoprotein (a) in patients with hyperlipidaemia. Eur J Clin Invest. 1995; 25 (9): 647-653
16. Slunga L, Johnson O, Dahlen GH, Eriksson S. Lipoprotein(a) and acute phase proteins in acute myocardial infarction. Scand J Clin Lab Invest. 1992; 52: 95-101.
17. Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein(a) concentrations in postmenopausal women taking norethisterone BMJ. 1991; 303 (6804): 694.
18. Shlipak MG, Simon JA, Vittinghof E, Conner EB, Knop RH. Estrogen and progestin, Lipoprotein(a), and the risk of recurrent coronary heart disease after menopause. JAMA. 2000; 12 (5): 242-248
19. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005; 90 (1): 493-500. (Pubitemid 40116699)
20. Lee S, Choi S, Kim HJ, Chung YS, Lee KW, Lee HC. Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in korean non-diabetic adults. J Korean Med Sci. 2006; 21: 695-700. (Pubitemid 44199326)
21. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16: 434-444 (Pubitemid 23046633)
22. Carantoni M, Zuliani G, Bader G, Palmieri E, Volpato S, Passaro A, et al. Low density lipoprotein cholesterol, lipoprotein(a), and apo(a) isoforms in the elderly: relationship to fasting insulin. Associazione Medica Sabin. Nutr Metab Cardiovasc Dis. 1999; 9 (5): 228-233
23. Inoue K, Nago N, Matsuo H, Goto T, Miyamoto T, Saegusa T, et al. Serum insulin and lipoprotein(a) concentrations. The Jichi Medical School Cohort Study. Diabetes Care. 1997; 20 (8): 1242-1247
24. Abu-Lebdeh HS, Hodge DO, Nguyen TT. Predictors of macrovascular disease in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2001; 76 (7): 707-712
25. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124 (1 Pt 2): 136-145 (Pubitemid 26011611)
26. Klaya F, Durlach V, Bertin E, Monier F, Monboisse JC, Gillery P. Evaluation of serum glycated lipoprotein(a) levels in non insulin-dependent diabetic patients. Clin Biochem. 1997; 30 (3): 227-230 (Pubitemid 27225356)
27. Alagozlu H, Gultekin F, Candan F. Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycaemic control in these patients? Nutr Metab Cardiovasc Dis. 2000; 10 (4): 204-208
28. Marcovina SM, Koschinsky ML, Lipoprotein(a) concentration and apolipoprotein(a) size A synergistic role in advanced atherosclerosis? Circulation.1999; 100: 1151-1153
29. Haffner SM, Morales PA, Stern MP, Gruber MK. Lp(a) concentrations in NIDDM. Diabetes. 1992; 41: 1267-1272
30. Erkelens DW. Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol. 2001; 11; 88 (7B): 38J-42J.
31. Kuusisto J, Lempiainen P, Mykkanen L, Laakso M. Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care. 2001; 24 (9): 1629-1633 (Pubitemid 33716461)
32. Laakso M. Insulin resistance and coronary heart disease. Curr Opin Lipidol. 1996; 7: 217-226 (Pubitemid 26280231)
33. Riemens SC, Ligtenberg JJ, Dullaart RP. Hyperglycemia-induced hyperinsulinemia acutely lowers plasma apolipoprotein B but not lipoprotein (a) in man. Clin Chim Acta. 1997; 261 (2): 149-158
34. Parhofer KG, Demant T, Ritter MM, Geiss HC, Markus Donner M, Schwandt P. Lipoprotein(a) metabolism estimated by nonsteady-state kinetics. Lipids. 1999; 34 (4): 325-335 (Pubitemid 29230272)
35. Wieringa G. Lipoiprotein(a): what's in a measure. Ann Clin Biochem. 2000; 37: 571-580